about
Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell VaccinesAntibody, T-cell and dendritic cell immunotherapy for malignant brain tumorsDendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trialsActive specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trialsClinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysisImmunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translationTumour Relapse Prediction Using Multiparametric MR Data Recorded during Follow-Up of GBM Patients.Childhood brain tumors: epidemiology, current management and future directions.Overview of cellular immunotherapy for patients with glioblastoma.Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination.Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?Molecular alterations in glioblastoma: potential targets for immunotherapy.Cytotoxic T-cells as imaging probes for detecting glioma.Immunotherapy of rat glioma without accumulation of CD4(+)CD25(+)FOXP3(+) regulatory T cellsPersonalized medicine for gliomasGalectin-1-mediated biochemical controls of melanoma and glioma aggressive behaviorClassifying Glioblastoma Multiforme Follow-Up Progressive vs. Responsive Forms Using Multi-Parametric MRI Features.Wilms' Tumour gene 1 (WT1) as an immunotherapeutic targetCellular immunotherapy for high-grade glioma.Galectin-1 and immunotherapy for brain cancer.Immunotherapy for the treatment of glioblastoma.Antitumor immune responses induced by ionizing irradiation and further immune stimulation.Dendritic cell vaccination in pediatric gliomas: lessons learnt and future perspectives.Glioblastoma multiforme: State of the art and future therapeutics.The graft-versus-neuroblastoma effect of allogeneic hematopoietic stem cell transplantation, a review of clinical and experimental evidence and a perspective on mechanisms.Current Studies of Immunotherapy on GlioblastomaBrain Tumor Immunotherapy: What have We Learned so Far?Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids in vitro.Vaccination strategies for neuro-oncology.Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response.Silencing IL-13Rα2 promotes glioblastoma cell death via endogenous signaling.Differentiation of human and murine induced pluripotent stem cells to microglia-like cells.Glioma and glioblastoma - how much do we (not) know?Treg infiltration in glioma: a hurdle for antiglioma immunotherapy.Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma.Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials.Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?Altered galectin-1 serum levels in patients diagnosed with high-grade glioma.Primary glioblastoma multiforme tumors and recurrence : Comparative analysis of the danger signals HMGB1, HSP70, and calreticulin.
P2860
Q26772715-72317631-40B5-4893-84FA-FD089C7F6C59Q27011298-F1181CDE-B1AD-4128-8406-D7379C10E0A7Q27014829-4BBB1B3C-D01A-4E20-8EAD-5B32C3FE41F6Q27026836-6719DD6B-B331-463F-A659-37AEC4460AC8Q27348437-9E05D279-59A7-46C0-BB7B-0D91ECFF8BFAQ28386858-662A5A88-C9CB-4BD0-977A-284B84EDB448Q30998509-847B4052-1233-4129-9598-4DC3BAFE407DQ33970971-50F95956-65B0-4C71-B5B4-7017A3ACA72FQ34189694-08C1051E-2FBD-4C29-A10D-AC4C9ADB61FCQ34242939-123476AA-F9BA-4AEF-BC11-41C6860D82D8Q34260758-C4F33E19-BC2B-4B07-829E-AEC1A09B6B77Q34383339-7E220459-1F3C-4A1A-AD70-727D08EC2AF6Q34870511-E73BC12A-D2D9-46D8-8204-D9F52460339BQ34983788-C4A1B084-AE0E-4186-B8C7-A2E0634EA372Q35020804-6B11ED88-6C03-47F1-9CA0-5498747469D9Q35114080-5FD91922-AF94-40AD-B4A9-FF103C1D8D04Q35228388-CDB6F741-E38F-47CF-AA46-8C488CA5C997Q37578230-E209BB2E-B80A-4416-91D9-FF23F7CDBF6AQ37704104-6A57C0A9-C9D8-4515-AC35-833FF9EE3318Q37851972-055E2D35-BC69-49D5-A369-E39927030A38Q37862237-F84F8293-F277-4A16-8E88-1099C486BCE1Q37980026-6BEDCF17-899E-4E84-A4A5-3E5519A9A940Q38139854-965C7E90-EE95-4C74-BB65-3D7406BF17E0Q38176625-EE3E297C-5FEC-49E1-9064-1E42A78DBA68Q38225874-80DC30CD-899B-499C-8EA2-2C80838F292FQ38243215-CF8DE3F6-146F-497B-9C84-221ECDB6407EQ38262914-7F7B7D42-EB45-4C19-9DE4-1F28099EF879Q38542113-02B3E8BF-2C7C-4987-99A2-BEC6AFF21B3FQ38617563-C59ED7DB-0FA7-4E3D-ACEC-6661F4982855Q38620079-DCBFFE59-908D-4C5D-83B6-3B2C8A365FD7Q38912265-98C7335B-E930-4F83-A87F-FA2C023BFDD4Q39539596-904C06D9-C10D-4718-BC5D-97EA78323EDAQ40311122-5B348175-9238-4FE6-ADBD-0E970D2A6B8DQ42578340-E9220AA1-5578-454B-9C45-591862FDBD49Q44315396-7DD7D582-5039-45D6-AB4B-209DB4370DBAQ46586294-5FEE194A-D311-4009-BD84-2C0494690968Q46597433-603B4BE6-078B-44A5-A2E9-B7592E0A114FQ48329275-3C8AF62D-FA63-4267-93BE-A5A295DF83DCQ50860307-1BDB5E90-AAC1-4607-9963-F37101E092B8Q52145169-9F594B2B-B2D1-4A00-8E7D-FE4702741250
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dendritic cell therapy of high-grade gliomas.
@en
Dendritic cell therapy of high-grade gliomas.
@nl
type
label
Dendritic cell therapy of high-grade gliomas.
@en
Dendritic cell therapy of high-grade gliomas.
@nl
prefLabel
Dendritic cell therapy of high-grade gliomas.
@en
Dendritic cell therapy of high-grade gliomas.
@nl
P2093
P2860
P1433
P1476
Dendritic cell therapy of high-grade gliomas
@en
P2093
Hilko Ardon
Sofie Van Cauter
Stefaan Van Gool
Tina Verschuere
P2860
P304
P356
10.1111/J.1750-3639.2009.00316.X
P577
2009-10-01T00:00:00Z